Breast Cancer (Tumor Markers)

Blood Test for Detection of Recurrent Cancer Approved

Published in Blood Weekly, April 22nd, 1996

Biomira Diagnostics Inc., Toronto, Ontario, Canada, announced that Truquant BR RIA was approved for marketing by the U.S. Food and Drug Administration (FDA).

Truquant BR RIA is the first breast tumor marker test to receive expedited review by the FDA, and is the first such test to be cleared for marketing in the United States. Truquant BR RIA is a blood test that can detect breast cancer recurrence in women previously treated for Stage II and Stage III breast cancer. There are currently more than one million women living in the United States who have been diagnosed with Stage II and Stage III breast cancer.

"Once you've had breast cancer, the fear...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1996-04-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry